immunology

HS-243 is an inhibitor of IRAK-4 and IRAK-1 with IC50s of 20 and 24 nM. HS-243 shows anti-inflammatory and anticancer activity.

Pirazolac (ZK-76604) is a novel non-steroidal anti-inflammatory agent for the study of rheumatoid arthritis.

INCB3619 is a selective and potent inhibitor of ADAM with antitumour effects, inhibiting ADAM10, ADAM17, MMP12 and MMP15.

JG26 is a potent inhibitor of ADAM17, which can inhibit ADAM8, ADAM17, ADAM10 and MMP-12, with IC50 values of 12 nM, 1.9 nM, 150 nM and 9.4 nM, respectively, and can be used to study the immune system of the body.

GSK040, a potent and highly selective inhibitor of BET BD2, exhibits a pIC50 of 8.3, demonstrating over 5000-fold selectivity against BET BD1 (pIC50=4.6). This compound is primarily utilized in oncology and immunology research [1].This compound is unstable in powder form and other related salt forms are recommended.

Ataquimast inhibits IL-5 secretion along with that of TNF-a, IL-4 and GM-CSF from human cells.

Benzyl cinnamate (Benzylcinnamoate) is a natural product isolated from various plant species,with anti-inflammatory activity.

beta-Escin is a natural mixture of triterpenoid saponins isolated from horse chestnut (Aesculus hippocastanum) seeds, can be used as a vasoprotective anti-inflammatory, anti-edematous and anti-nociceptive agent.

Tamarixetin (4'-O-Methyl Quercetin) is a natural flavonoid derivative of quercetin that exhibits anti-inflammatory and antioxidative effects, offering protection against cardiac hypertrophy.

3-Epicorosolic acid has a potent inhibitory effect on Epstein-Barr virus early antigen (EBV-EA) induction, it has potential anti-inflammatory activities as well as cancer chemopreventive activity.3-Epicorosolic acid shows both potent α-glucosidase and pro

Izeltabart Tapatansine (IMGC-936) is a CHO-expressing humanized next-generation medetonin-based ADC compound targeting ADAM9-expressing tumors, and exhibits cytotoxicity against ADAM9-positive human tumor cell lines for cancer research.

Chlorthenoxazine (Chlorethylbenzmethoxazone) has anti-inflammatory activity.

Anti-inflammatory agent 34 shows moderate acute anti-inflammatory activity and analgesic activity in vivo.

Bucolome (Paramidine) is a CYP2C9 inhibitor with uricosuric and anti-inflammatory activity.

CG347B is a selective inhibitor of HDAC6.

Sericoside, a triterpenoid compound, is obtained from Terminalia and exhibits potent anti-inflammatory properties. Additionally, sericoside displays robust lipolytic activity, thereby aiding in the reduction of skin wrinkles and improvement of skin texture.

ZLDI-8 is an inhibitor of Notch activating cleaving enzyme ADAM-17 and inhibits the cleavage of Notch protein.

Fendosal (HP-129) is a non-steroidal anti-inflammatory agent. It is 6.9 to 9.5 times more active than aspirin in the prophylactic and therapeutic adjuvant-induced polyarthritis models of chronic inflammation.

SpeB cysteine protease is a potent modifier capable of degrading proteins that are crucial for both host and bacterial immunology. It can break down streptolysin O (SLO) contained within extracellular vesicles.

Monophosphoryl Lipid A-12 (free acid) functions as a toll-like receptor 4 agonist, primarily utilized in immunology and vaccine research.

ZM522 is a CD73 inhibitor with an IC50 value of 0.56 μM. It effectively increases interferon-gamma (INF-γ) levels and enhances immune activity by modulating T cell activation. ZM522 holds potential for research in immunology and anti-cancer fields.

HPK1-IN-54 (Compound 16) is a potent inhibitor of HPK1 (hematopoietic progenitor kinase 1), enhancing T cell activation and proliferation by blocking HPK1 activity to exert antitumor effects. It has an IC50 of 2.67 nM for HPK1, showing excellent selectivity over the MAP4K family (>100-fold) and other selected kinases (>300-fold). HPK1-IN-54 exhibits moderate in vivo clearance and reasonable oral exposure in both mice and rats. Additionally, in the CT26 mouse colon cancer model, HPK1-IN-54 demonstrates significant antitumor activity and shows a synergistic effect when combined with anti-PD-1 therapy. HPK1-IN-54 holds promise for research in the field of immunology.

1,2,3,4,7,8,9-Heptachlorodibenzofuran (1,2,3,4,7,8,9-HpCDF) is a chemical compound known for inducing the expression of CYP1A1 and CYP1B1 genes in human peripheral blood lymphocytes, while also enhancing the expression of the aromatic hydrocarbon receptor repressor (AhRR). In isolated human peripheral blood lymphocytes, it boosts ethoxyresorufin-O-deethylase (EROD) activity—a marker for CYP1A1 activity—in a concentration-dependent manner. Additionally, 1,2,3,4,7,8,9-HpCDF exhibits immunosuppressive properties, reducing the number of plaque-forming cells in mouse spleens and increasing aromatic hydrocarbon hydroxylase (AHH) activity in the liver microsomes of mice injected with sheep red blood cells. This compound is pertinent to research in the fields of immunology, metabolic diseases, and environmental toxicology.

KB-208 is a phagocytosis inhibitor that enhances immune thrombocytopenia (ITP) in mouse models at a dosage of 1 mg kg. It does not alter other blood parameters or increase serum toxicity biomarkers and is applicable for research in the field of immunology.